CA2570570A1 - Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide - Google Patents

Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide Download PDF

Info

Publication number
CA2570570A1
CA2570570A1 CA002570570A CA2570570A CA2570570A1 CA 2570570 A1 CA2570570 A1 CA 2570570A1 CA 002570570 A CA002570570 A CA 002570570A CA 2570570 A CA2570570 A CA 2570570A CA 2570570 A1 CA2570570 A1 CA 2570570A1
Authority
CA
Canada
Prior art keywords
polysaccharide
composition
cancer
backbone
carbohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002570570A
Other languages
English (en)
French (fr)
Inventor
David Platt
Eliezer Zomer
Anatole Klyosov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pro Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2570570A1 publication Critical patent/CA2570570A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002570570A 2004-06-22 2005-06-21 Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide Abandoned CA2570570A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58195804P 2004-06-22 2004-06-22
US60/581,958 2004-06-22
PCT/US2005/021827 WO2006002106A2 (en) 2004-06-22 2005-06-21 Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide

Publications (1)

Publication Number Publication Date
CA2570570A1 true CA2570570A1 (en) 2006-01-05

Family

ID=35782284

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002570570A Abandoned CA2570570A1 (en) 2004-06-22 2005-06-21 Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide

Country Status (6)

Country Link
EP (1) EP1765365A4 (de)
JP (1) JP2008503583A (de)
CN (1) CN101267828A (de)
BR (1) BRPI0512394A (de)
CA (1) CA2570570A1 (de)
WO (1) WO2006002106A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723987C (en) 2008-05-14 2019-06-11 Agriculture Victoria Services Pty Ltd Use of angiogenin or angiogenin agonists for treating diseases and disorders
AU2013204721B2 (en) * 2008-05-14 2016-08-18 Agriculture Victoria Services Pty Ltd Methods for treating cachexia
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
AU2013204740C1 (en) * 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
FR3022462B1 (fr) * 2014-06-18 2018-04-27 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Composition orale d'anticorps anti-tnfalpha

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US20020107222A1 (en) * 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
EP0958825A1 (de) * 1998-05-18 1999-11-24 Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) Synergistische Zusammensetzung zur Behandlung von Krebs, welche unverdauliche Kohlenhydrate und eines Antikrebsmittel enthält
DE50012701D1 (de) * 1999-09-06 2006-06-08 Guenther Beisel Vernetztes mittel zur erzeugung eines langanhaltenden sättigungseffekts und verfahren zu dessen herstellung
US7012068B2 (en) * 2001-03-27 2006-03-14 Pro-Pharmaceuticals, Inc. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
KR20040045795A (ko) * 2002-11-25 2004-06-02 주식회사한국신약 펠리누스 린테우스에서 추출한 다당류와 마이토마이신ｃ를 포함하는 복합 항암제

Also Published As

Publication number Publication date
EP1765365A2 (de) 2007-03-28
JP2008503583A (ja) 2008-02-07
BRPI0512394A (pt) 2008-03-11
CN101267828A (zh) 2008-09-17
WO2006002106A2 (en) 2006-01-05
EP1765365A4 (de) 2008-02-20
WO2006002106A3 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
KR101561860B1 (ko) 비항응고성 다당류 조성물
Norrby Low‐molecular‐weight heparins and angiogenesis
TWI862506B (zh) 用於治療纖維性粘連的經高度純化及/或經修改聚海藻糖（fucan）組成物
Wieboldt et al. Glycosaminoglycans in cancer therapy
ITRM20000041A1 (it) Derivati glicosamminoglicani parzialmente desolfatati non anticoagulanti ad attivita' antiangiogenica.
BG66191B1 (bg) Полизахариди с антитромболитична активност, които съдържат поне една ковалентна връзка с биотин или производно на биотин
Lee et al. Doxorubicin covalently conjugated heparin displays anti-cancer activity as a self-assembled nanoparticle with a low-anticoagulant effect
Nagano et al. Chondroitin sulfate protects vascular endothelial cells from toxicities of extracellular histones
US9387256B2 (en) Tissue targeting
US20020107222A1 (en) Modified polysaccharides for treatment of cancer
Cai et al. Multifunctionalized brush-like glycopolymers with high affinity to P-selectin and antitumor metastasis activity
US9572831B2 (en) Composition and method for sulfated non-anticoagulant low molecular weight heparins in cancer and tumor metastasis
CA2570570A1 (en) Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide
ES2458818T3 (es) Métodos para evaluar la actividad de una composición de polisacárido
US20070258969A1 (en) Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers
US20050282773A1 (en) Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer
JP6444399B2 (ja) 癌の処置に用いるための硫酸化多糖
US11458107B2 (en) Abiotic anti-VEGF nanoparticle
WO2004064777A2 (en) Modified polysaccharides combination with anti-cancer drugs for enhanced treatment of cancer
Alberto Passi Proceedings of the XXXIX National Meeting of the Italian Society for the Study of Connective Tissues (SISC)
파자나 Designing functional formulations of a taurocholate conjugated low molecular weight heparin derivative for targeting tumor angiogenesis and metastasis

Legal Events

Date Code Title Description
FZDE Discontinued